Armo Diagnostics

Summary Statement of Deficiencies D5417 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(d) (d) Reagents, solutions, culture media, control materials, calibration materials, and other supplies must not be used when they have exceeded their expiration date, have deteriorated, or are of substandard quality. This STANDARD is not met as evidenced by: Based on observation and interview with laboratory staff, the laboratory had supplies available for use after their expiration date. Findings follow: A) During a tour of the laboratory on 3/30/26 at 2:40pm, 1 of 1 Drug Alteration Test Strips, lot: HUAD-164, B30764-06, AR2403001, expiration date 2/28/26, and 1 of 1 Phase Scientific Indicaid Covid-19 Rapid Antigen Test, lot: 24090030, REF 2110400, expiration date 12/18/25 were observed in the laboratory, available for use beyond the expiration date. B) In an interview on 3/30/26 at 2:40pm the technical supervisor confirmed that the items, identified above, had exceeded their expiration date and were available for use in the laboratory. D5791 ANALYTIC SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1289(a)(c) (a) The laboratory must establish and follow written policies and procedures for an ongoing mechanism to monitor, assess, and when indicated, correct problems identified in the analytic systems specified in 493.1251 through 493.1283. This STANDARD is not met as evidenced by: Based on review of the laboratory's quality control Levy-Jennings charts for January and February of 2026, review of QA review notes, lack of documentation, and interview it was determined that the laboratory failed to assess or take corrective Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- action when the Amphetimine controls exhibited a shift. Findings follow: A) Review of Levy Jennings reports from January and February controls (High, Medium, Low and End Run) for Amphetimine assays performed in the lab showed a negative bias on 107 of 112 data points. B) Upon request, the laboratory was unable to provide documentation that the shiftnoted by the surveyor, had been identified or

Summary Statement of Deficiencies D2009 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(1) The individual testing or examining the samples and the laboratory director must attest to the routine integration of the samples into the patient workload using the laboratory's routine methods. This STANDARD is not met as evidenced by: Review of the proficiency test attestation records for three events in 2023 and 2024, lack of documentation, and interviews with laboratory staff, determined that personnel failed to attest to the routine integration of proficiency test samples in the patient workload on two of the three events reviewed. Survey findings follow: A) Review of the attestation forms for the College of American Pathologists (CAP) Drug Monitoring for Pain Management (DMPM) proficiency testing program 2023 event A, 2023 event B, and 2024 event A, revealed that the attestations for 2023 event A and 2024 event A lacked the signatures of the laboratory director or designee and the testing personnel. B) In an interview, at 11:28 a.m. on 6/18/24, the laboratory staff member (# 1 as identified on a separate staff identification list) confirmed the attestation form was not signed by the laboratory director and testing personnel for CAP DMPM event A in 2023 and CAP DMPM event A in 2024. D5413 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(b) The laboratory must define criteria for those conditions that are essential for proper storage of reagents and specimens, accurate and reliable test system operation, and test result reporting. The criteria must be consistent with the manufacturer's instructions, if provided. These conditions must be monitored and documented and, if applicable, include the following: (1) Water quality. (2) Temperature. (3) Humidity. (4) Protection of equipment and instruments from fluctuations and interruptions in Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- electrical current that adversely affect patient test results and test reports. This STANDARD is not met as evidenced by: Observations made during a tour of the laboratory, review of temperature records, review of specimen and reagent storage requirements, and interview with laboratory staff determined that the laboratory failed to monitor the temperatures of two of five freezers in which patient urine samples and reagents were stored. Findings follow: A) During a tour of the laboratory at 09:15 a.m. on 6/18/24 the surveyor observed a freezer in the specimen accession room, four freezers (labeled freezer #1 through freezer #4) in the main laboratory, and an unlabeled freezer, which was empty and not running, in the main laboratory. B) In an interview at 09:15 a.m. on 6/18/24, the laboratory staff member (# 1 on the CMS 209 form) said that the unlabeled freezer was not in use since it "quit working" in early May of 2024 and was replaced by a new freezer. C) Review of temperature records for May 2024 revealed computer recorded spread-sheets were provided with device names of 'Freezer 1", "Freezer 2", "ARMO Freezer", "ARMO Room 4", and "ARMO Refrigerator". D) Review of the temperature records for May 2024 revealed a computer recorded spread-sheet labeled Freezer 2. The temperatures ranged from a low of 22.5 degrees centigrade (C) to a high of 24.7 degrees C. all or within range of expected ambient room temperature ( not freezer temperature). E) When asked to verify the identity of the devices reported on the temperature records, the laboratory staff member (#1 on the CMS 209 form) noted the monitor serial numbers on the temperature sensing devices and confirmed with the conrtacted firm which monitors the temperatures remotely that the records for "Freezer 2" were for the unlabeled freezer, the records for "ARMO freezer" were for the freezer labeled #2, and the temperatures for "Freezer 1" were for the freezer labeled #4. F) When asked for the temperature recordings for the freezers labeled #1 and #3 on 6/18/24 at 2:55 p.m., the laboratory staff member (#1 on the CMS 209 form) confirmed they were not available. G) On 6/18/24 at 2:45 p.m. the laboratory staff member #1 said that if temperatures were outside of acceptable range, that laboratory staff would be notified and

Summary Statement of Deficiencies D5311 SPECIMEN SUBMISSION, HANDLING, AND REFERRAL CFR(s): 493.1242(a) The laboratory must establish and follow written policies and procedures for each of the following, if applicable: (1) Patient preparation. (2) Specimen collection. (3) Specimen labeling, including patient name or unique patient identifier and, when appropriate, specimen source. (4) Specimen storage and preservation. (5) Conditions for specimen transportation. (6) Specimen processing. (7) Specimen acceptability and rejection. (8) Specimen referral. This STANDARD is not met as evidenced by: Through review of laboratory policy and procedure, observation and interview it was determined that the laboratory failed to label three of three specimen collection containers with patient name or unique patient identifier. Findings follow: A) During a tour of the laboratory on 9/7/22 at 1:57 pm three urine specimens containers were observed in the laboratory refrigerator labeled with the patient's first name and last initial only with those labels written on the lid of the container. B) Review of the laboratory policy and procedure revealed that specimen containers are to be labeled with the patient's first and last names and a unique identifier or the patient's date of birth. C) In an interview on 9/7/22 at 2:05 pm , the laboratory staff member (#1 on the CMS 209 form) confirmed that the specimens identified above lacked proper patient identification on the containers as required by policy and procedure. D5317 SPECIMEN SUBMISSION, HANDLING, AND REFERRAL CFR(s): 493.1242(d) If the laboratory accepts a referral specimen, written instructions must be available to the laboratory's clients and must include, as appropriate, the information specified in paragraphs (a)(1) through (a)(7) of this section. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- This STANDARD is not met as evidenced by: Through lack of documentation and interview it was determined that the laboratory did not provide written instructions to clents detailing requirements for specimen collection, labeling, storage and handling/shipping requirements to the laboratory's clients. A) Upon request, the laboratory was unable to provide a copy of written instructions provided to clients for specimen collection, labeling, storage and handling /shipping. B) In an interview on 9/7/22 at 1:57 pm the laboratory staff member (#2 on the CMS 209 form) stated that a laboratory representative gave verbal instructions to clients when establishing accounts but no written instructions or manual was provided. D5805 TEST REPORT CFR(s): 493.1291(c) The test report must indicate the following: (c)(1) For positive patient identification, either the patient's name and identification number, or a unique patient identifier and identification number. (c)(2) The name and address of the laboratory location where the test was performed. (c)(3) The test report date. (c)(4) The test performed. (c)(5) Specimen source, when appropriate. (c)(6) The test result and, if applicable, the units of measurement or interpretation, or both. (c)(7) Any information regarding the condition and disposition of specimens that do not meet the laboratory's criteria for acceptability. This STANDARD is not met as evidenced by: Through a review of seven Laboratory Results reports and interviews with laboratory personnel it was determined the laboratory test reports failed to include the address of the laboratory location where the test was performed on seven of the seven reports reviewed. Survey findings include: A) Seven of seven patient Laboratory Results reports reviewed contained results labeled "In Office Point of Care Results" for drugs of abuse screening. B) In an interview at 1:15 on 9/7/22 the laboratory staff member ( #1 as listed on the form CMS-209) stated that the laboratory provides clients with kits for waived drugs of abuse screening and the clients perform the tests and list results on test order and the results are not flagged with the performing laboratory's name and address. The staff member further stated that the client having a valid CLIA certificate was not confirmed. D6032 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(14) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(14) Specify, in writing, the responsibilities and duties of each consultant and each person, engaged in the performance of the preanalytic, analytic, and postanalytic phases of testing, that identifies which examinations and procedures each individual is authorized to perform, whether supervision is required for specimen processing, test performance or results reporting, and whether consultant or director review is required prior to reporting patient test results. -- 2 of 3 -- This STANDARD is not met as evidenced by: Through a review of Personnel Records for seven of twelve personnel listed on the form CMS-209, through a lack of documentation, and through interviews with laboratory staff, it was determined the laboratory director failed to give written authorization to seven of seven randomly selected testing personnel who perform highly complex drug testing. Survey findings include: A) The surveyor reviewed Staff Laboratory personnel files for seven randomly selected testing personnel (listed as #5, #8, #9, #12 and #14 on the form CMS-209) who perform highly complex quantitative drug testing and found no written authorization signed by the laboratory director to perform testing for any of the personnel. B) Upon request, the laboratory was unable to provide written authorization to perform testing signed by the laboratory director for the personnel identified above. C) In an interview, at 10:05 a.m.on 9/7/22, laboratory employee (#2 on the CMS 209 form) confirmed written authorization to perform testing signed by the laboratory director is not present. -- 3 of 3 --